Cholestatic Jaundice Induced by Duloxetine in a Patient with Major Depressive Disorder
Psychiatry Investigation
;
: 228-230, 2010.
Artigo
em Inglês
| WPRIM
| ID: wpr-148394
ABSTRACT
Duloxetine is a balanced and potent serotonin and noradrenaline reuptake inhibitor (SNRI) and has adverse effects that are commonly associated with such drugs, including nausea, dry mouth, constipation, insomnia, and dizziness. Recently, duloxetine-induced liver injury has also been observed in patients with preexisting liver disease or chronic alcohol use. We investigated the effects of duloxetine in a healthy young adult with major depressive disorder (MDD) but no risk factors, and found that his total bilirubin level increased to 3.3 mg/dL and he developed jaundice after 5 months of duloxetine treatment. Discontinuation of duloxetine treatment saw his total bilirubin level decrease to 1.8 mg/dL. Thus, the administration of duloxetine might induce liver injury in a patient with MDD. However, the limitations of this single case report must be acknowledged. Although the cause of hepatic dysfunction in this case remains to be elucidated, clinicians should monitor liver function carefully after duloxetine treatment. Further investigations with a larger sample are needed.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Compostos Organotiofosforados
/
Tiofenos
/
Bilirrubina
/
Serotonina
/
Norepinefrina
/
Fatores de Risco
/
Constipação Intestinal
/
Icterícia Obstrutiva
/
Transtorno Depressivo Maior
/
Tontura
Tipo de estudo:
Estudo de etiologia
/
Fatores de risco
Limite:
Humanos
Idioma:
Inglês
Revista:
Psychiatry Investigation
Ano de publicação:
2010
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS